RVM-V002
/ RVAC Medicines
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 16, 2023
Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals
(clinicaltrials.gov)
- P1b | N=24 | Terminated | Sponsor: RVAC Medicines (US), Inc. | N=48 ➔ 24 | Trial completion date: Feb 2024 ➔ Sep 2023 | Active, not recruiting ➔ Terminated; Changes in COVID-19 pandemic landscape
Enrollment change • Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease
June 26, 2023
Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals
(clinicaltrials.gov)
- P1b | N=48 | Active, not recruiting | Sponsor: RVAC Medicines (US), Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease
March 28, 2023
Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals
(clinicaltrials.gov)
- P1b | N=48 | Recruiting | Sponsor: RVAC Medicines (US), Inc.
New P1 trial • Infectious Disease • Novel Coronavirus Disease
1 to 3
Of
3
Go to page
1